




Interim Results

Six months ended 30 September 2016



Disclaimer

The information in this document and the related presentation do not constitute or form any part of, and should not be construed as, an offer or invitation to sell, or issue, or any solicitation of any offer to purchase, subscribe for or otherwise acquire any share or other securities in Omega Diagnostics Group PLC ("Omega") in any jurisdiction, nor shall it or any part of it form the basis of, or be relied on in connection with, any contract therefore. No reliance may be placed for any purpose whatsoever on the information or opinions contained in this document and the presentation or their completeness. No representation or warranty, expressed or implied, is given on behalf of Omega or any of its respective directors, employees, agents or advisers as to the accuracy, completeness or fairness of the information or opinions contained herein or made in the presentation and, save in the case of fraud, no responsibility or liability is accepted (and all such liability is hereby excluded) for any such information or opinions.

The information in this document may not be reproduced or further distributed to any other person or published, in whole or in part, for any purpose. Neither this document (or any copy of it) nor the information in the presentation may be sent or taken into the United States, Canada, Australia or Japan, nor may it be distributed to any US person (within the meaning of regulation S under the US Securities Act of 1933, as amended).

Furthermore, this document and presentation are strictly only for persons who are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 (SI 2001/1335), as amended, (the "FPO") or persons falling within paragraph 49 of the FPO (high net worth companies, unincorporated associations etc.) or to persons to whom it may otherwise be lawful for these materials to be communicated ("Permitted Recipients"). Any persons who are not Permitted Recipients should not stay for the remainder of this presentation and, in any event, must not act or rely upon the information contained in this presentation and document. By staying for the remainder of this presentation and/or receiving this document, each participant is deemed to confirm that they are a Permitted Recipient.

Omega Presentation Team

- Andrew Shepherd – Chief Executive Officer
- Kieron Harbinson – Chief Financial Officer
- Jag Grewal – Sales & Marketing Director

Introduction


- Financials
- Core business update
- Allergy update
- Global Health / VISITECT® CD4 / Pune update
- Summary

Financial KPIs

Six months ending 30 September 2016


Sales (£m)

£6.8m ▲ 11%



Adjusted PBT (£m)

£0.56m ▲ 8%



- Gross margin improvement of 2 percentage points
- Investment in additional resource in UK and Pune, India
- Reduced tax credit so adjusted EPS maintained at 0.6p


Adjusted PBT stated before acquisition costs, share-based payments, IFRS-related discount unwinds and amortisation of intangible assets

Capitalised development – IAS38

Six months ending 30 September 2016

Allersys®/Allergodip expenditure

Cumulative spend to date of £4.7m




£631k

62% of FY16 run rate

Visitect® CD4 expenditure

Cumulative spend to date of £1.9m



£309k

63% of FY16 run rate

Group cash flow

Six months ending 30 September 2016

	2016	2015
EBITDA	£0.7m	£0.7m
Working capital/other movements	(£0.1m)	(£0.1m)
Investing activity	(£1.2m)	(£1.0m)
(Decrease)/increase in cash	(£0.6m)	(£0.4m)
Opening cash	£1.3m	£2.0m
Forex	£0.1m	-
Closing cash	£0.8m	£1.6m

Core Business

Allergy and Autoimmune

Main products:

- Allergozyme
- Allergodip
- Genesis Elisa

£1.76m
(↑11%)

Food Intolerance

Main products:

- Genarrayt[®]/Foodprint[®] Microarray
- Food Detective[®]
- CNS laboratory service


£3.84m
(↑15%)

Infectious Diseases

Main products:

- Immutrep Syphilis
- Micropath Bacterial tests
- Dengue Elisa

£1.23m (↑1%)



Decline now arrested.
Favourable Euro currency impact.
Plan to reverse fortunes with Allergodip[®] / Allergodip[®] App for export markets.



Continued organic growth in India.
Increased focus on Food Intolerance products.
Investment in business development.
SAARC Country coverage


Flagship Product Sales

Six months ending 30 September 2016

Genarray[®]/FoodPrint[®] Reagent Sales

Top five markets = 67% of sales


Strong growth particularly in North America and Middle East



Food Detective Sales

Top five markets = 62% of sales

Maturing markets
Switch to lab testing
Stocking / phasing






Approached by IDS with a view to changing the nature of the commercial relationship

- Format lock achieved
- Ambient Temperature Effect issue now resolved
- 112 patients tested with no significant difference in test result between 20-35°C when compared to 'gold-standard' flow cytometry
- 488 patients tested across three UK testing sites demonstrating capability to meet Sensitivity and Specificity targets for visual read
- Successful manufacturing of components for R&D scale-up to 10,000-device batch size. Work ongoing to ensure process robustness.

Development Roadmap leading to commercial launch



- Demand significant, estimated at 22-23 million tests p.a. (Source: DMM meeting - WHO/UNAIDS March 2016)

VISITECT® CD4

External Field Trials

- Evaluations in the pipeline for India and France in Q1 calendar 2017
- Saving Lives at Birth (SLAB) studies pending ethics approval at maternity units in South Africa and Kenya in Q1 calendar 2017
- Multi-site study in preparation and coordinated by INGO at centres in sub-Saharan Africa

Rapid Test Manufacturing Pune, India



- Stage 1 QMS audit complete – ISO accreditation expected soon
- Recommended for Manufacturing Licence
- Early performance data for malaria RDTs promising
- Plan to launch CE-Marked VISITECT® Malaria and VISITECT® Pregnancy Q1 calendar 2017
- Manufacturing capacity for menu extension in Global Health




- Product strategy is to provide market-leading test performance, convenience and affordable pricing for use at the point-of-care
- Pre-launch took place this month of three rapid test products at American Society for Tropical Medicine and Hygiene (ASTMH) conference, Atlanta, US
- In-house performance data showing good results
- We intend to submit to FIND/WHO product testing to access national tenders in low and middle-income countries

VISITECT® Malaria

Significant demand

VISITECT® Malaria

Lateral flow RDTs
Easy-to-use
Rapid
Robust and reliable
Comply with WHO guidelines



Global **challenges** • Global **solutions**



- Expected demand – to increase by 100m tests to c. 380m tests in 2016 (Source: UNITAID)

Summary

- Core business continues to perform well
- 41 Allersys® allergen panel CE Marked & first purchase order received
- VISITECT® CD4 – we expect to launch in H2 calendar 2017 subject to field trials
- VISITECT® Malaria - confident we will launch from our Pune manufacturing site in Q1 calendar 2017
- In discussion with IDS over future commercial relationship

APPENDICES

Introduction

Omega is focused on selling a wide range of specialist products, primarily in the immunoassay, in-vitro diagnostics (IVD) market within three segments:

- Allergy and Autoimmune
- Food Intolerance
- Infectious Diseases



Our Mission:

To improve human health and well-being through innovative diagnostic tests and global partnerships.

A Brief History

1987

Omega Diagnostics Ltd founded



2007

Acquisition of Genesis Diagnostics and Cambridge Nutritional Sciences

G·E·N·E·S·I·S
Diagnostics



2010

Acquisition of IVD Division of Allergopharma

Signing of exclusive license agreement with IDS



2012



CD4 test licensed from Burnet Institute

2006

Omega Diagnostics Group PLC IPO

2009

Acquisition of Co-Tek

2011

Formation of Indian subsidiary:

Omega Dx (Asia) Pvt Ltd



2015

Establish Pune RDT manufacturing facility




Food Intolerance Product Range

- Food Detective



- Genarrayt / Foodprint




Allergy Segment



Core laboratory segment

- Automation
- Developed world markets
- Allersys® strategy



Mid market ELISA


- Semi-automated
- Declining market
- Holding strategy



Small lab / doctors office

- Manual
- Screening/panel tests
- Emerging markets
- Allergodip® / OmegApp strategy

VISITECT® CD4 role in HIV Testing



VISITECT® CD4 is designed for use at community and primary care health-care levels in low- and middle-income countries

Omega Senior Management Team

